An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.

Sanfilippo Syndrome Clinical Trial

Official title:
An Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Mucopolysaccharidosis Type IIIA Disease

Status Terminated

Clinical Trial Summary

This extension study will allow participants to continue receiving treatment with HGT-1410 and to initiate treatment in patients who received no-treatment in Study HGT-SAN-093, and will evaluate the long-term safety and efficacy of the study drug.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02350816
Study type	Interventional
Source	Takeda
Contact
Status	Terminated
Phase	Phase 2
Start date	April 8, 2015
Completion date	April 12, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00383448` - HSCT for High Risk Inherited Inborn Errors	Phase 2
Terminated	`NCT04088734` - Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease	Phase 1/Phase 2
Not yet recruiting	`NCT06333041` - Study of Cannabidiol in Sanfilippo Syndrome	Phase 2/Phase 3
Recruiting	`NCT05705674` - The Natural History Study of Patients With Sanfilippo Disease(s) (MPS3)
Active, not recruiting	`NCT02716246` - Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH	Phase 2/Phase 3
Terminated	`NCT01299727` - Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)	Phase 1/Phase 2
Completed	`NCT02060526` - Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease	Phase 2